Doxorubicin

Doxorubicin (CAS 23214-92-8) is an anthracycline antibiotic commonly used as an anti-cancer agent targeting DNA replication machinery. Its mechanism of action involves intercalation into DNA double helices and subsequent inhibition of DNA topoisomerase II, impeding DNA synthesis and causing genomic instability. Additionally, Doxorubicin mediates chromatin remodeling by facilitating histone displacement from active chromatin, contributing further to DNA damage and transcriptional dysregulation. It is extensively employed in studies involving hematologic malignancies, solid tumors, and sarcomas, frequently serving as a chemotherapeutic reference compound. In biochemical assays, Doxorubicin has demonstrated inhibitory effects on Topoisomerase II with an IC50 typically ranging between 1-10 µM, depending on assay conditions and cell lines applied.

References:
[1]Brayfield, A, ed. (2013). Doxorubicin. Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 15 April 2014.
[2]Pommier Y., et al. (2010). DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chemistry & Biology 17 (5): 421–433.
[3]Pang, B., et al. (2013). Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nature Communications 4 (5): 1908
[4]Boucek RJ., et al. (1987). The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J of Biol Chem 262: 15851-15856.